Nifty
Sensex
:
:
10607.35
36033.06
-195.35 (-1.81%)
-660.63 (-1.80%)

Pharmaceuticals & Drugs - Global

Rating :
59/99  (View)

BSE: 532531 | NSE: STAR

411.10
-7.05 (-1.69%)
14-Jul-2020 | 3:55PM
  • Day's Open
  • Day's High
  • Day's Low
  • Previous Close
  •  418.15
  •  418.95
  •  407.70
  •  418.15
  • Volume
  • Traded Value (lacs)
  • 52 Week High
  • 52 Week Low
  •  435103
  •  1788.71
  •  547.65
  •  268.00

Stock Summary

  • Market Cap(Crs)
  • Stock P:E
  • Face Value
  • 3,743.93
  • 102.91
  • 10
  • Enterprise Value(Crs)
  • Dividend Yield
  • Price:Book Value
  • 6,448.75
  • 0.72%
  • 1.48

Shareholding Pattern

  • Promoter
  • Corporate
  • Public
  • 31.27%
  • 0.00%
  • 12.97%
  • FII
  • DII
  • Others
  • 28.8%
  • 15.10%
  • 11.86%

Chart

Price | P:E | P:BV | EV:EBITDA

Revenue CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • -
  • 20.29
  • -7.67

EBITDA CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • -
  • 14.48
  • -2.73

PAT CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • -
  • 198.64
  • -2.26

P:E (Median)

  • 8 Years
  • 5 Years
  • 3 Years
  • 8.15
  • 23.24
  • 10.21

P:BV (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 3.01
  • 2.80
  • 1.77

EV:EBITDA (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 22.62
  • 14.96
  • 12.78

Quarterly Results

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 20
Mar 19
Var%
Dec 19
Dec 18
Var%
Sep 19
Sep 18
Var%
Jun 19
Jun 18
Var%
Net Sales
619
616
0%
732
570
29%
715
520
38%
686
473
45%
Expenses
554
524
6%
552
509
8%
568
476
20%
565
430
31%
EBITDA
65
92
-30%
181
61
196%
147
44
233%
121
43
183%
EBIDTM
11%
15%
25%
11%
20%
8%
18%
9%
Other Income
18
17
4%
14
10
41%
14
10
43%
10
6
58%
Interest
40
23
73%
40
22
81%
40
17
134%
35
17
111%
Depreciation
45
30
53%
43
28
56%
42
31
36%
43
29
48%
PBT
-173
72
-
127
35
268%
162
1
22997%
46
1
8166%
Tax
-10
-8
-
11
0
-
7
-6
-
3
-14
-
PAT
-163
80
-
116
35
233%
154
6
2373%
43
14
206%
PATM
-26%
13%
16%
6%
22%
1%
6%
3%
EPS
-18.15
8.91
-
12.92
3.88
233%
17.22
0.70
2360%
4.82
1.57
207%

Annual Results

Consolidated Figures in Rs. Crores /

Standalone
Description
TTM
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Dec 12
Dec 11
Dec 10
Dec 09
Net Sales
2,752
3,012
3,344
3,826
2,862
1,196
1,341
962
2,550
1,696
1,305
Net Sales Growth
26%
-10%
-13%
34%
139%
-11%
39%
-62%
50%
30%
 
Cost Of Goods Sold
1,122
1,466
1,379
1,281
1,502
560
715
492
1,264
806
701
Gross Profit
1,629
1,546
1,966
2,545
1,360
635
626
470
1,286
890
604
GP Margin
59%
51%
59%
67%
48%
53%
47%
49%
50%
52%
46%
Total Expenditure
2,239
2,562
3,109
3,309
2,482
967
1,118
861
2,059
1,369
1,118
Power & Fuel Cost
-
55
51
34
77
16
19
13
54
30
25
% Of Sales
-
2%
2%
1%
3%
1%
1%
1%
2%
2%
2%
Employee Cost
-
443
434
419
358
172
157
120
303
220
177
% Of Sales
-
15%
13%
11%
12%
14%
12%
13%
12%
13%
14%
Manufacturing Exp.
-
119
116
137
119
41
36
44
90
64
45
% Of Sales
-
4%
3%
4%
4%
3%
3%
5%
4%
4%
3%
General & Admin Exp.
-
207
194
173
199
86
66
58
182
159
87
% Of Sales
-
7%
6%
5%
7%
7%
5%
6%
7%
9%
7%
Selling & Distn. Exp.
-
173
209
161
130
61
67
40
116
88
73
% Of Sales
-
6%
6%
4%
5%
5%
5%
4%
5%
5%
6%
Miscellaneous Exp.
-
99
725
1,104
97
29
58
94
50
3
73
% Of Sales
-
3%
22%
29%
3%
2%
4%
10%
2%
0%
1%
EBITDA
513
450
236
517
381
229
223
101
491
327
187
EBITDA Margin
19%
15%
7%
14%
13%
19%
17%
10%
19%
19%
14%
Other Income
56
322
921
398
102
39
60
34
32
70
24
Interest
156
205
196
183
168
47
109
79
195
147
76
Depreciation
174
172
194
199
131
64
56
31
104
64
49
PBT
162
395
766
533
184
156
118
24
223
186
85
Tax
11
14
21
51
42
148
41
11
39
45
22
Tax Rate
7%
4%
3%
10%
30%
99%
45%
2%
14%
24%
15%
PAT
151
373
681
399
113
2
51
712
224
122
110
PAT before Minority Interest
156
378
701
446
100
1
51
713
234
141
121
Minority Interest
6
-5
-20
-46
14
1
0
-1
-10
-19
-11
PAT Margin
5%
12%
20%
10%
4%
0%
4%
74%
9%
7%
8%
PAT Growth
12%
-45%
71%
253%
7,111%
-97%
-93%
217%
83%
12%
 
EPS
16.81
41.62
76.04
44.57
12.64
0.18
5.68
79.51
25.05
13.67
12.24

Results Balance Sheet

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Dec 12
Dec 11
Dec 10
Dec 09
Shareholder's Funds
2,649
2,464
2,749
2,658
1,145
1,007
2,026
1,371
1,283
831
Share Capital
90
90
89
89
60
60
59
58
58
89
Total Reserves
2,552
2,365
2,651
2,563
1,084
947
1,964
1,310
1,223
724
Non-Current Liabilities
2,348
2,067
2,049
2,760
286
306
901
1,133
2,013
1,459
Secured Loans
1,806
1,551
1,623
2,615
250
274
731
1,054
1,387
779
Unsecured Loans
0
0
15
12
17
1
0
0
622
678
Long Term Provisions
22
17
25
14
6
17
57
66
0
0
Current Liabilities
2,703
1,899
3,104
1,892
1,020
707
1,797
2,792
924
684
Trade Payables
894
712
774
775
234
262
463
585
420
445
Other Current Liabilities
250
130
819
348
502
127
652
1,370
305
65
Short Term Borrowings
1,339
944
1,394
700
203
225
600
685
0
0
Short Term Provisions
220
113
117
68
80
93
83
152
199
174
Total Liabilities
7,853
6,585
8,035
7,360
2,469
2,096
4,796
5,342
4,492
3,233
Net Block
3,567
2,903
2,909
2,679
701
555
3,017
3,188
2,328
1,857
Gross Block
4,046
3,229
3,186
2,825
1,081
907
3,514
3,645
2,627
2,081
Accumulated Depreciation
479
326
277
147
379
353
498
457
298
224
Non Current Assets
4,808
4,101
4,243
3,845
1,040
788
3,384
3,711
2,521
2,283
Capital Work in Progress
506
620
780
815
171
99
241
285
191
85
Non Current Investment
494
350
316
127
69
42
0
0
2
341
Long Term Loans & Adv.
224
197
223
202
97
90
119
230
0
0
Other Non Current Assets
17
31
16
23
2
1
7
9
0
0
Current Assets
3,045
2,484
3,792
3,515
1,429
1,309
1,411
1,625
1,960
950
Current Investments
285
311
1,280
1,214
561
401
0
0
0
0
Inventories
871
552
733
613
208
176
442
480
312
233
Sundry Debtors
987
882
996
1,033
390
364
483
538
384
420
Cash & Bank
517
303
329
312
147
231
166
260
339
91
Other Current Assets
386
139
210
246
124
136
320
347
925
205
Short Term Loans & Adv.
249
296
244
98
54
79
44
92
850
151
Net Current Assets
342
584
688
1,623
410
601
-386
-1,166
1,037
266
Total Assets
7,853
6,585
8,035
7,360
2,469
2,096
4,796
5,342
4,492
3,233

Cash Flow

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Dec 12
Dec 11
Dec 10
Dec 09
Cash From Operating Activity
60
187
288
73
83
-272
134
457
324
90
PBT
344
706
497
146
992
2,890
949
273
186
143
Adjustment
95
-275
191
346
-757
-2,775
-416
114
179
43
Changes in Working Capital
-323
-191
-341
-342
-96
-261
-311
129
-2
-82
Cash after chg. in Working capital
116
241
347
150
139
-146
223
515
363
103
Interest Paid
0
0
0
0
0
0
0
0
0
0
Tax Paid
-56
-54
-59
-77
-56
-126
-89
-58
-39
-14
Other Direct Exp. Paid
0
0
0
0
0
0
0
0
0
0
Extra & Other Items
0
0
0
0
0
0
0
0
0
0
Cash From Investing Activity
-148
583
-687
-2,225
52
4,077
807
-656
-941
-148
Net Fixed Assets
-48
677
-237
-536
-67
-119
-38
-18
-43
-27
Net Investments
-383
748
-143
-1,479
78
249
-509
78
654
-578
Others
283
-842
-307
-210
40
3,947
1,353
-716
-1,552
458
Cash from Financing Activity
194
-1,016
338
2,944
-421
-3,319
-990
89
850
92
Net Cash Inflow / Outflow
106
-246
-60
792
-286
487
-49
-110
233
34
Opening Cash & Equivalents
256
515
1,111
299
586
132
212
325
79
46
Closing Cash & Equivalent
366
256
515
1,111
298
586
132
212
325
79

Financial Ratios

Consolidated /

Standalone
Description
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Dec 12
Dec 11
Dec 10
Dec 09
Book Value (Rs.)
295
274
306
297
192
169
344
233
220
190
ROA
5%
10%
6%
2%
0%
1%
14%
5%
4%
4%
ROE
15%
27%
17%
5%
0%
3%
42%
18%
14%
21%
ROCE
11%
16%
11%
8%
11%
8%
21%
13%
12%
11%
Fixed Asset Turnover
0.83
1.04
1.27
1.47
1.21
0.61
0.27
0.82
0.72
0.80
Receivable days
113
102
97
91
115
115
193
66
86
106
Inventory Days
86
70
64
52
58
84
175
56
59
57
Payable days
115
116
117
76
77
113
253
93
120
129
Cash Conversion Cycle
85
56
44
68
96
86
115
30
25
33
Total Debt/Equity
1.22
1.03
1.35
1.34
0.78
0.54
0.79
1.94
1.58
1.79
Interest Cover
3
5
4
2
4
2
10
2
2
3

News Update


  • Strides Pharma’s arm gets nod for Butalbital, Acetaminophen, Caffeine, Codeine Phosphate Capsules
    9th Jul 2020, 09:54 AM

    The company has 124 cumulative ANDA filings with USFDA of which 87 ANDAs have been approved and 37 are pending approval

    Read More
  • Strides Pharma’s arm gets USFDA nod for Triamcinolone Acetonide Ointment
    2nd Jun 2020, 11:44 AM

    The product will be manufactured at the company’s flagship facility at Bangalore

    Read More
  • Strides Pharma Science develops, commences export of Favipiravir Antiviral tablets
    29th Apr 2020, 10:04 AM

    The product is a generic version of Avigan of Toyama Chemical, Japan

    Read More
  • Strides Pharma’s arm gets USFDA’s approval for Flucytosine Capsules
    20th Apr 2020, 11:31 AM

    The product will be manufactured at the company’s flagship facility at Bangalore and will be marketed by Strides Pharma Inc. in the US market

    Read More

Source: www.accordfintech.com. Price feed provided by www.nseindia.com and www.bseindia.com value addition by www.accordfintech.com. Intraday data delayed 15 minutes.

DISCLAIMER: Information is provided " as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.